1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40-50.
Article PubMed
2. Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia 2017;60:2129-38.
Article PubMed
3. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82.
Article
4. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes-2019. Diabetes Care 2019;42:S173-81.
PubMed
5. Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. Mass Spectrom Rev 2019;38:221-38.
Article PubMed
6. Guasch-Ferre M, Hruby A, Toledo E, Clish CB, Martinez-Gonzslez MA, Salas-Salvado J, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care 2016;39:833-46.
Article PubMed PMC
7. Klein MS, Shearer J. Metabolomics and type 2 diabetes: translating basic research into clinical application. J Diabetes Res 2016;2016:3898502.
Article PubMed
8. Batch BC, Hyland K, Svetkey LP. Branch chain amino acids: biomarkers of health and disease. Curr Opin Clin Nutr Metab Care 2014;17:86-9.
PubMed
9. Giesbertz P, Daniel H. Branched-chain amino acids as biomarkers in diabetes. Curr Opin Clin Nutr Metab Care 2016;19:48-54.
Article PubMed
10. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol 2014;10:723-36.
Article PubMed PMC
11. Sun L, Liang L, Gao X, Zhang H, Yao P, Hu Y, et al. Early prediction of developing type 2 diabetes by plasma acylcarnitines: a population-based study. Diabetes Care 2016;39:1563-70.
Article PubMed
12. Bi X, Henry CJ. Plasma-free amino acid profiles are predictors of cancer and diabetes development. Nutr Diabetes 2017;7:e249.
Article PubMed PMC
13. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 2005;38:296-309.
Article PubMed
14. Zhao YY, Cheng XL, Vaziri ND, Liu S, Lin RC. UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin Biochem 2014;47:16-26.
Article
15. Ceglarek U, Leichtle A, Brugel M, Kortz L, Brauer R, Bresler K, et al. Challenges and developments in tandem mass spectrometry based clinical metabolomics. Mol Cell Endocrinol 2009;301:266-71.
Article PubMed
16. Denoroy L, Zimmer L, Renaud B, Parrot S. Ultra high performance liquid chromatography as a tool for the discovery and the analysis of biomarkers of diseases: a review. J Chromatogr B Analyt Technol Biomed Life Sci 2013;927:37-53.
Article PubMed
17. Human experimentation: code of ethics of the world medical association (Declaration of Helsinki). Can Med Assoc J 1964;91:619.
PubMed PMC
18. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4.
PubMed
19. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 2018;41:S13-27.
PubMed
20. Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep learning-based multi-omics integration robustly predicts survival in liver cancer. Clin Cancer Res 2018;24:1248-59.
Article PubMed
21. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res 2018;46:W486-94.
Article PubMed PMC
22. Yip WCY, Sequeira IR, Plank LD, Poppitt SD. Prevalence of pre-diabetes across ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of dysglycaemia. Nutrients 2017;9:1273.
Article PMC
23. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130-9.
Article PubMed
24. Yang XJ, Zou SF, Xu Y, Li Y, Yang SS. The influence of intensive lifestyle intervention on patients with isolated impaired fasting glucose: a meta-analysis. J Adv Nurs 2016;72:2587-97.
Article PubMed
25. Chen T, Ni Y, Ma X, Bao Y, Liu J, Huang F, et al. Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations. Sci Rep 2016;6:20594.
Article PubMed PMC
26. Xu F, Tavintharan S, Sum CF, Woon K, Lim SC, Ong CN. Metabolic signature shift in type 2 diabetes mellitus revealed by mass spectrometry-based metabolomics. J Clin Endocrinol Metab 2013;98:E1060-5.
Article PubMed
27. Ottosson F, Smith E, Melander O, Fernandez C. Altered asparagine and glutamate homeostasis precede coronary artery disease and type 2 diabetes. J Clin Endocrinol Metab 2018;103:3060-9.
Article PubMed
28. Owei I, Umekwe N, Stentz F, Wan J, Dagogo-Jack S. Amino acid signature predictive of incident prediabetes: a case-control study nested within the longitudinal pathobiology of prediabetes in a biracial cohort. Metabolism 2019;98:76-83.
Article PubMed PMC
29. Yu E, Papandreou C, Ruiz-Canela M, Guasch-Ferre M, Clish CB, Dennis C, et al. Association of tryptophan metabolites with incident type 2 diabetes in the PREDIMED trial: a case-cohort study. Clin Chem 2018;64:1211-20.
Article PubMed PMC
30. Matsuoka K, Kato K, Takao T, Ogawa M, Ishii Y, Shimizu F, et al. Concentrations of various tryptophan metabolites are higher in patients with diabetes mellitus than in healthy aged male adults. Diabetol Int 2016;8:69-75.
Article PubMed PMC
31. McCoin CS, Knotts TA, Adams SH. Acylcarnitines: old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol 2015;11:617-25.
Article PubMed PMC
32. Batchuluun B, Al Rijjal D, Prentice KJ, Eversley JA, Burdett E, Mohan H, et al. Elevated medium-chain acylcarnitines are associated with gestational diabetes mellitus and early progression to type 2 diabetes and induce pancreatic β-cell dysfunction. Diabetes 2018;67:885-97.
Article PubMed PMC
33. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009;139:1073-81.
PubMed PMC
34. Rutkowsky JM, Knotts TA, Ono-Moore KD, McCoin CS, Huang S, Schneider D, et al. Acylcarnitines activate proinflammatory signaling pathways. Am J Physiol Endocrinol Metab 2014;306:E1378-87.
Article PubMed PMC
35. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2018;14:88-98.
Article PubMed
36. Afshinnia F, Nair V, Lin J, Rajendiran TM, Soni T, Byun J, et al. Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians. JCI Insight 2019;4:e130317.
Article PMC